Learn how GLP-1 medications may impact oral contraceptive absorption and discover provider-recommended strategies for safe, effective birth control use.
GLP-1 receptor agonists, such as semaglutide, may be prescribed for weight management and blood sugar control. These medications slow gastric emptying, which may influence the absorption of oral medications, including contraceptives.
This guide explores the interaction between GLP-1 and various contraceptive methods, offering recommendations. Eden connects patients with licensed providers who prescribe only GLP-1 medications, ensuring safe and tailored care.
GLP-1 receptor agonists, including semaglutide, liraglutide, and dulaglutide, slow gastric emptying, which can delay the absorption of orally administered medications. However, studies have shown that this delay does not significantly impact the overall effectiveness of oral contraceptives for most GLP-1 medications. An exception is tirzepatide, which has been associated with a reduction in the bioavailability of oral contraceptives.
While most GLP-1 medications do not affect oral contraceptive efficacy, patients are advised to:
Non-oral contraceptive methods are not affected by GLP-1 medications and include:
Barrier methods, such as condoms and diaphragms, remain effective and can be used alone or in conjunction with other contraceptive methods for added protection.
GLP-1 receptor agonists are not recommended during pregnancy due to potential risks observed in animal studies, including fetal growth restriction and skeletal abnormalities. Patients planning to conceive should discontinue GLP-1 therapy at least one to two months prior to conception, depending on the specific medication.
Weight loss associated with GLP-1 therapy may improve fertility, particularly in individuals with polycystic ovary syndrome (PCOS). Patients not planning to become pregnant should use effective contraception during GLP-1 therapy to prevent unintended pregnancies.
Common side effects of GLP-1 medications, such as nausea, vomiting, and diarrhea, may affect the absorption of oral contraceptives. Patients experiencing these symptoms should consult their healthcare providers to discuss alternative contraceptive methods or additional precautions.
GLP-1 medications and hormonal contraceptives can be used concurrently with appropriate precautions. Patients should consult with healthcare providers to determine the most suitable contraceptive method during GLP-1 therapy, considering potential interactions and individual health factors.
This content is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting or adjusting any medication, including birth control or GLP-1 therapy.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
